Clinical Trials Logo

Plasmacytoma clinical trials

View clinical trials related to Plasmacytoma.

Filter by:

NCT ID: NCT00007995 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Patients Who Have Multiple Myeloma or Primary Systemic Amyloidosis

Start date: July 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: This phase II trial is studying how well chemotherapy and peripheral stem cell transplant work in treating patients with multiple myeloma or primary systemic amyloidosis.

NCT ID: NCT00006890 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Start date: July 12, 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Thalidomide may stop the growth of multiple myeloma by stopping blood flow to the tumor. Prednisone may be effective in preventing relapse of multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of two doses of thalidomide combined with prednisone following peripheral stem cell transplantation in treating patients who have multiple myeloma.

NCT ID: NCT00006466 Active, not recruiting - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Beta Alethine in Treating Patients With Myeloma

Start date: August 2000
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Biological therapies such as beta alethine use different ways to stimulate the immune system and stop cancer cells from growing. PURPOSE: Phase I/II trial to study the effectiveness of beta alethine in treating patients who have myeloma.

NCT ID: NCT00006379 Completed - Lymphoma Clinical Trials

Non-Ablative Allo HSCT For Hematologic Malignancies or SAA

Start date: June 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by peripheral stem cell transplantation in treating patients who have hematologic cancer or aplastic anemia.

NCT ID: NCT00006362 Completed - Lymphoma Clinical Trials

PS-341 in Treating Patients With Advanced Cancer

Start date: November 1999
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced cancer.

NCT ID: NCT00006348 Completed - Lymphoma Clinical Trials

Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment

Start date: October 2000
Phase: Phase 3
Study type: Interventional

RATIONALE: Antiemetic drugs, such as ondansetron, may help to reduce or prevent nausea and vomiting in patients with advanced cancer. PURPOSE: This randomized phase III trial is studying how well ondansetron works compared to a placebo in treating patients with advanced cancer and chronic nausea and vomiting that is not caused by cancer therapy.

NCT ID: NCT00006232 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Combination Chemotherapy in Treating Patients With Stage II or Stage III Multiple Myeloma

Start date: October 1996
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which combination chemotherapy regimen is more effective for multiple myeloma. PURPOSE: This randomized phase III trial is comparing two combination chemotherapy regimens to see how well they work in treating patients with stage II or stage III multiple myeloma.

NCT ID: NCT00006225 Completed - Breast Cancer Clinical Trials

Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer

Start date: November 1999
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of peripheral stem cell transplantation in treating patients who have breast cancer or hematologic cancer.

NCT ID: NCT00006220 Terminated - Lymphoma Clinical Trials

Arsenic Trioxide With or Without Tretinoin in Treating Patients With Hematologic Cancer That Has Not Responded to Previous Therapy

Start date: June 1999
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Tretinoin may help hematologic cancer cells develop into normal white blood cells. PURPOSE: Phase I/II trial to study the effectiveness of arsenic trioxide with or without tretinoin in treating patients who have hematologic cancer that has not responded to previous therapy.

NCT ID: NCT00006219 Completed - Clinical trials for Multiple Myeloma and Plasma Cell Neoplasm

Chemoprevention Therapy in Treating Patients at High Risk of Developing Multiple Myeloma

Start date: August 2000
Phase: Phase 2
Study type: Interventional

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Dehydroepiandrosterone and clarithromycin may be effective in preventing multiple myeloma. PURPOSE: Randomized phase II trial to compare the effectiveness of dehydroepiandrosterone with that of clarithromycin in treating patients who may be at a high risk of developing multiple myeloma.